Gene Sequencing

In a federal class action, shareholders claim directors of Illumina (gene sequencing) issued misleading earnings estimates, and when true earnings were reported the share price sank by 24.8% in one day, from $224.85 to $139.

SAN DIEGO – In a federal class action, shareholders claim directors of Illumina (gene sequencing) issued misleading earnings estimates, and when true earnings were reported the share price sank by 24.8% in one day, from $224.85 to $139.